2010
DOI: 10.1016/j.ejphar.2010.05.046
|View full text |Cite
|
Sign up to set email alerts
|

The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
10
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(11 citation statements)
references
References 44 publications
1
10
0
Order By: Relevance
“…Similar results were obtained by previous studies [Richard et al, 2011;Colak et al, 2012;Warpe et al, 2015]. ECG revealed significant prolongation of QT interval in DOX-administered groups (II, III) as reported by Rahimi_Balaei et al [2010]; Ashour et al [2011] and Warpe et al [2015]; denoting delayed repolarization and a negative chronotropic effect [Gandhi et al, 2013] or metabolic and electrolyte abnormalities associated with developed heart failure [Hunter et al, 2008].…”
Section: Discussionsupporting
confidence: 88%
“…Similar results were obtained by previous studies [Richard et al, 2011;Colak et al, 2012;Warpe et al, 2015]. ECG revealed significant prolongation of QT interval in DOX-administered groups (II, III) as reported by Rahimi_Balaei et al [2010]; Ashour et al [2011] and Warpe et al [2015]; denoting delayed repolarization and a negative chronotropic effect [Gandhi et al, 2013] or metabolic and electrolyte abnormalities associated with developed heart failure [Hunter et al, 2008].…”
Section: Discussionsupporting
confidence: 88%
“…Lithium is used for the treatment of bipolar disorder, via the inhibition of glycogen synthase kinase-3β enzyme (GSK-3β) (Lenox andHahn, 2000, Phiel andKlein, 2001). Many clinical and experimental studies showed that lithium from ranges 10 to 400 mg/kg caused neuroprotection in different conditions (Boyko et al, 2015, Chrislip et al, 1984, Dhawan et al, 1999, Frey et al, 2006, Hajek and Weiner, 2016, Khairova et al, 2012, Machado-Vieira et al, 2009, Rahimi et al, 2014, Rahimi_Balaei et al, 2010. Several clinical reviews showed that optimum lithium concentration after therapeutic doses is 0.6-0.75 mmol/L.…”
Section: Introductionmentioning
confidence: 95%
“…The selection of doses of MPH was done according to previous work results on neurodegenerative doses of MPH in animal models and human subjects (Balcioglu, Ren, 2009, Gerasimov, Franceschi, 2000, Hannestad, Gallezot, 2010, Motaghinejad, Motevalian, 2015e, Quinn, Wigal, 2004, Schiffer, Volkow, 2006, Teo, Stirling, 2002, Thanos, Robison, 2015, Volkow, Wang, 2001, Wargin, Patrick, 1983, and neuroprotective doses of lithium was obtained from previous work on human and animal studies (Boyko, Nassar, 2015, Chrislip, Anger, 1984, Dhawan, Singh, 1999, Frey, Valvassori, 2006, Hajek and Weiner, 2016, Khairova, Pawar, 2012, Machado-Vieira, Manji, 2009, Rahimi, Dehpour, 2014, Rahimi_Balaei, Momeny, 2010. There are several references in relation to clinical relevance of choosing MPH and lithium doses in our experiment, and also the relationship that exist between doses and plasma levels in experimental subjects (Balcioglu, Ren, 2009, Hanak, Chevillard, 2014, Morrison, Pritchard, 1971, Severus, Kleindienst, 2007, Severus, Kleindienst, 2008, Teo, Stirling, 2002, Thanos, Robison, 2015, Wargin, Patrick, 1983 Elevated Plus Maze (EPM) was used to assess anxiety in animal models.…”
mentioning
confidence: 99%
“…Iron may catalyse ROS formation in Dox-induced cardiotoxicity 4 , 5 , and DEX may chelate iron before it catalyses the conversion of O 2 •− and H 2 O 2 to more damaging oxidants 25 . According to previous studies 26 28 , we established a rat model of cumulative cardiotoxicity, Dox and Dox combined with DEX were given for 4 or 8 weeks, respectively. Detections of plasma cTnT and Ca-Mg-ATP revealed that significant cardiotoxicity was achieved after 4-week and 8-week Dox treatment, but DEX could efficiently alleviate Dox-induced cardiac damage.…”
Section: Discussionmentioning
confidence: 99%